Cancer is the abnormal proliferation of physiologically inadequate cells. Studies have identified the cardiac pacemaker pocket as a site of rare neoplasms. To evaluate the clinical outcomes, treatment, prognosis, and individualized management of tumors originating in the cardiac pacemaker pocket, a systematic review was conducted using case reports and case series available in the PubMed/Medline, Science Direct, Cochrane Central, LILACS, and Scientific Electronic Library Online (Scielo) databases. Pacemaker pocket tumors affected patients with a mean age of 72.9 years, with a higher incidence in males (76.9%, n = 10). The average time for neoplasm development was 4.4 years (54.07 months). The most prevalent model was Medtronic (38.4%, n = 5), with titanium (83.3%) being the most common metal composition. Chemotherapy was the most performed procedure among patients (38.4%), followed by radiation therapy (38.4%) and surgical tumor resection (30.7%). Six analyzed cases (46.1%) resulted in death, and four patients (30.7%) achieved a cure. Patients with pacemakers should be routinely evaluated for the occurrence of malignant tumors at the site of device implantation.
癌症是生理功能异常细胞的异常增殖。研究已确认心脏起搏器囊袋为罕见肿瘤的发生部位。为评估起源于心脏起搏器囊袋肿瘤的临床结局、治疗方式、预后及个体化管理策略，本研究通过检索PubMed/Medline、Science Direct、Cochrane Central、LILACS及科学在线图书馆（Scielo）数据库中的病例报告与病例系列进行系统综述。起搏器囊袋肿瘤患者平均年龄为72.9岁，男性发病率更高（76.9%，n=10）。肿瘤发生的平均时间为4.4年（54.07个月）。最常见起搏器型号为美敦力（38.4%，n=5），钛金属材质最为普遍（83.3%）。化疗是最常实施的治疗方案（38.4%），其次为放射治疗（38.4%）和肿瘤手术切除（30.7%）。六例分析病例（46.1%）最终死亡，四例患者（30.7%）获得治愈。建议对植入心脏起搏器的患者常规评估装置植入部位的恶性肿瘤发生情况。
Malignant Neoplasms Arising in the Cardiac Pacemaker Cavity: A Systematic Review
肿瘤(癌症)患者之家